Rigel Announces Presentations at American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting
Thursday October 27, 7:30 am ET
SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that two presentations related to its research program in rheumatoid arthritis (RA) will be made at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting, which is taking place November 4-9 at the Anaheim Convention Center in Anaheim, California.
Details are as follows:
Presentation Time: Monday, November 7, 1:15 p.m. PST
Title: An Orally Bioavailable Inhibitor of Syk Kinase (R406) Inhibits
Human Basophil CD63 Expression Following Ex Vivo Fc epsilon
Receptor Stimulation
Presentation Time: Monday, November 7, 1:30 p.m. PST
Title: A Multiple Dose Pharmacokinetic and Pharmacodynamic Study of an
Orally Bioavailable Inhibitor of Syk-Kinase (R406)
Rigel has focused its RA program on the development of oral, safe, disease modifying anti-rheumatic drugs (DMARD's). The company's product candidates are intended to be used early in the course of the disease to prevent the progression of major bone and cartilage destruction. R788, an oral formulation of R406, is Rigel's lead product candidate. Phase I trial results, to date, have demonstrated that R788 was safe and well-tolerated. In preclinical studies, Rigel's compound greatly diminished the swelling and tissue destruction associated with RA.
About Rigel (www.rigel.com)
Rigel is a late-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in allergy/asthma, rheumatoid arthritis and cancer. |
